Table 1.

SIRs and AER for second primary malignancies among CML patients from 1992–2009 (person: 8,511, person years: 31,614.37)

Secondary cancers	Observed	O/E	CI (95 %)	Excess risk*
All sites	473	1.27#	1.16–1.39	32.09
All sites excluding non-melanoma skin	470	1.27#	1.16–1.39	31.64
All solid tumors	375	1.14#	1.02–1.26	14.14
Oral cavity and pharynx	23	2.73#	1.73–4.09	4.61
Digestive system	97	1.29#	1.05–1.58	6.95
Esophagus	3	0.72	0.15–2.09	−0.38
Stomach	10	1.38	0.66–2.54	0.87
Small intestine	2	1.34	0.16–4.85	0.16
Colon, rectum and anus	54	1.26	0.94–1.64	3.49
Liver, gallbladder, intrahep bile duct and other biliary	15	1.89#	1.06–3.11	2.23
Pancreas	12	1.2	0.62–2.09	0.62
Respiratory system	72	1.27	0.99–1.6	4.82
Lung, bronchus, trachea, mediastinum and other resp org	65	1.23	0.95–1.56	3.78
Soft tissue including heart	2	1.02	0.12–3.7	0.02
Skin excluding basal and squamous	20	1.32	0.81–2.04	1.55
Breast	34	0.88	0.61–1.23	−1.51
Female breast	33	0.86	0.59–1.21	−1.66
Male breast	1	1.94	0.05–10.79	0.15
Female genital system	11	0.74	0.37–1.33	−1.2
Cervix uteri	3	1.74	0.36–5.1	0.4
Corpus and uterus, nos	4	0.52	0.14–1.33	−1.17
Ovary	3	0.72	0.15–2.11	−0.36
Male genital system	70	0.9	0.7–1.13	−2.53
Prostate	67	0.87	0.68–1.11	−3.05
Urinary system	32	1	0.68–1.41	0.01
Urinary bladder	17	0.82	0.48–1.32	−1.16
Kidney and renal pelvis	13	1.24	0.66–2.13	0.81
Brain and other nervous system	5	1.28	0.42–2.99	0.35
Endocrine system	8	1.72	0.74–3.4	1.06
Thyroid	6	1.4	0.51–3.05	0.54
Adrenal gland	2	16.90#	2.05–61.04	0.6
All lymphatic and hematopoietic diseases	78	2.49#	1.97–3.11	14.78
Lymphoma	40	2.43#	1.74–3.31	7.45
Myeloma	5	1	0.32–2.33	0
Leukemia	33	3.37#	2.32–4.73	7.34
Mesothelioma	2	1.9	0.23–6.86	0.3
Kaposi sarcoma	2	3.47	0.42–12.53	0.45
Miscellaneous	17	2.02#	1.18–3.24	2.72

* excess risk per 10,000

^# P < 0.05